Anavex Life Sciences Corp (AVXL)

[Doc328]

There is just one newer publication --- likely in press at JPAD

The other reference is to the 148 week data from the remaining patients in the 2a trial published back in 2020.
https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/trc2.12013

The MAA is supported by data from the randomized, double-blind, placebo-controlled Phase IIb/III, ANAVEX®2-73-AD-004 trial and it’s up to 144 week open-label-extension (OLE) ATTENTION-AD ANAVEX®2-73-AD-EP-004 trial investigating blarcamesine in early Alzheimer’s disease. Former study was recently accepted in a peer-reviewed medical journal with focus on Alzheimer’s disease titled, “Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.”


Strengthening the submission is the 265 week (~5-year) Phase 2a trial investigating blarcamesine in mild-to-moderate Alzheimer’s disease, with interim preliminary data published in the peer-reviewed medical journal, Alzheimer’s & Dementia, titled: “A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2-73) Phase 2a clinical study.”